(Q46124973)

19 December 2017

title

At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity (English)

1 reference

19 December 2017

diffuse large B-cell lymphoma

0 references

1 reference

1 reference

9

1 reference

19 December 2017

Nicolas Dulphy

10

1 reference

19 December 2017

Catherine Thieblemont

8

Catherine Thieblemont

1 reference

19 December 2017

Zena Khaznadar

4

Zena Khaznadar

1 reference

19 December 2017

Ryad Tamouza

6

Ryad Tamouza

1 reference

19 December 2017

Guylaine Henry

2

Guylaine Henry

1 reference

19 December 2017

Daniela Geromin

3

Daniela Geromin

1 reference

19 December 2017

author name string

Anne Danielou-Lazareth

1

1 reference

19 December 2017

Josette Briere

5

1 reference

19 December 2017

Jean-Michel Cayuela

7

1 reference

19 December 2017

language of work or name

English

0 references

publication date

11 March 2013

1 reference

19 December 2017

European Journal of Immunology

published in

1 reference

19 December 2017

volume

43

1 reference

19 December 2017

issue

5

1 reference

19 December 2017

page(s)

1383-1388

1 reference

19 December 2017

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

Rituximab: mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

Low natural killer cell activity in patients with malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

The microenvironment in mature B-cell malignancies: a target for new treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

Up on the tightrope: natural killer cell activation and inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

4-1BB signaling beyond T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

The biology of human natural killer-cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

inferred from DOI database lookup

7 January 2021

based on heuristic

An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201242733

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/EJI.201242733

1 reference

19 December 2017

1 reference

19 December 2017